EVALUATION OF THE EFFECT OF INTRAVITREAL BEVACIZUMAB INJECTION ON SCLERAL THICKNESS WITH ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY

Year 2018, Volume: 1 Issue: 2, 31 - 35, 25.11.2018

Mustafa Eliaçık , Sevil Karaman Erdur

Abstract

Abstract

Purpose:
To evaluate the changes of scleral thickness after repeated intravitreal
injections of bevacizumab in a consecutive series of patients with anterior
segment optical coherence tomography (AS-OCT).

Materials
and Methods: The study group consisted of 54
eyes of 54 consecutive phakic patients who were indicated for the first time
for intravitreal bevacizumab injection with a follow-up time of at least 12
months. The fellow eye of each patient formed the control group. Scleral
thickness at the injection side was measured before the first intravitreal injection
and after re-injections using AS-OCT.

Results:
Before treatment, scleral thickness was 610.5±22.9μm at the injection site and
608.17±22.2 μm at the same quadrant in fellow eye. After treatment scleral
thickness was 604.8±22.3 μm at the injection site and 607.2±19.2 μm at the same
quadrant in fellow eye. There was no statistically significant change both at
injection site and other quadrants in the study and fellow eye at the end of
follow-up period. The mean injection number was 9.44 ± 0.76. There was no
significant correlation between the changes in scleral thickness and injection
numbers (r=0.43, p=0.365).

Conclusions:
Well-controlled intraocular pressure after intravitreal injections and more importantly
molecular weight of injected material could probably prevent scleral thinning.

Keywords

intravitreal injections, sclera, optical coherence tomography, retina

References

• 1. Sari A, Adiguzel U, Canacankatan N, et al: Effects of intravitreal bevacizumab in repeated doses: an experimental study. Retina 2009; 29:1346-1355. 2. Brucker AJ: Age-related macular degeneration. Retina 2009;29 (6 Suppl):S2-4 3. Koss MJ, Naser H, Sener A, et al: Combination therapy in diabetic macular oedema and retinal vein occlusion--past and present. Acta Ophthalmol. 2012;90:580-589. 4. Costagliola C, Romano M, Corte MD, et al: Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study. Retina 2009;29:1227-1234. 5. Moschos MM, Brouzas D, Apostolopoulos M, et al: Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 2007;114:37-44. 6. Costagliola C, Semeraro F, Cipollone U, et al: Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: prospective trial on 156 eyes throughout 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2009;247:1031-1037. 7. Zinkernagel MS, Schorno P, Ebneter A, et al: Scleral thinning after repeated intravitreal injections of antivascular endothelial growth factor agents in the same quadrant. Invest Ophthalmol Vis Sci 2015;56:1894-1900. 8. Zheng X, Sakai H, Goto T, et al: Anterior segment optical coherence tomography analysis of clinically unilateral pseudoexfoliation syndrome: evidence of bilateral involvement and morphologic factors related to asymmetry. Invest Ophthalmol Vis Sci 2011;52:5679-5684. 9. Console JW, Sakata LM, Aung T, et al: Quantitative analysis of anterior segment optical coherence tomography images: the Zhongshan Angle Assessment Program. Br J Ophthalmol 2008;92:1612-1616. 10. Yoo C, Eom YS, Suh YW, et al: Central corneal thickness and anterior scleral thickness in Korean patients With Open-angle glaucoma: an anterior segment optical coherence tomography study. J Glaucoma 2011;20:95-99. 11. Kwong TQ, Mohamed M: Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. Br J Clin Pharmacol 2014; 78:699-706. 12. Palmer JM, Amoaku WM, Kamali F: Quality of bevacizumab compounded for intravitreal administration. Eye 2013; 27:1090-1097. 13. Sivaprasad S, Hykin P: What is new in the management of wet age-related macular degeneration? Bri Med Bull 2013;105:201-211. 14. Ozkaya A, Alkin Z, Agca A, et al: One-year results of treatment with bevacizumab alone or ranibizumab alone for low visual acuity due to neovascular age-related macular degeneration. J Ocul Pharmacol Ther 2013;29:865-869. 15. Tolentino M: Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95-113. 16. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al: Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81-87. 17. Mohamed-Noor J, Bochmann F, Siddiqui MA, et al: Correlation between corneal and scleral thickness in glaucoma. J Glaucoma 2009;18:32-36. 18. Oliveira C, Tello C, Liebmann J, et al: Central corneal thickness is not related to anterior scleral thickness or axial length. J Glaucoma 2006;15:190-194. 19. Olsen TW, Aaberg SY, Geroski DH, et al: Human sclera: thickness and surface area. Am J Ophthalmol 1998;125:237-241. 20. Li H, Leung CK, Cheung CY, et al: Repeatability and reproducibility of anterior chamber angle measurement with anterior segment optical coherence tomography. Br J Ophthalmol 2007;91:1490-1492. 21. Buckhurst H, Gilmartin B, Cubbidge RP, et al: Ocular biometric correlates of ciliary muscle thickness in human myopia. Ophthalmic Physiol Opt 2013;33:294-304. 22. Taban M, Lowder CY, Ventura AA, et al: Scleral thickness following fluocinolone acetonide implant (Retisert). Ocul Immunol Inflamm 2010;18:305-313. 23. Myles ME, Neumann DM, Hill JM: Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005;57: 2063–2079. 24-Geroski DH, Edelhauser HF: Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001;52:37– 48.
• 25. Turgut B, Demir T, Celiker U: The effects of injection site on the reflux following intravitreal injections. J Clin Med Res 2009;1:280-284. 26. Downs JC, Ensor ME, Bellezza AJ, et al: Posterior scleral thickness in perfusion-fixed normal and early-glaucoma monkey eyes. Invest Ophthalmol Vis Sci 2001;42:3202-3208. 27. Lee SB, Geroski DH, Prausnitz MR, et al: Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp Eye Res 2004;78:599-607.